Trillium Asset Management LLC Trims Stake in Johnson & Johnson (NYSE:JNJ)

Trillium Asset Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 3.3% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 15,012 shares of the company’s stock after selling 516 shares during the quarter. Trillium Asset Management LLC’s holdings in Johnson & Johnson were worth $2,338,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of JNJ. State Street Corp lifted its holdings in Johnson & Johnson by 1.1% in the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock valued at $23,476,323,000 after acquiring an additional 1,568,633 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the period. Geode Capital Management LLC boosted its stake in shares of Johnson & Johnson by 2.0% during the second quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock worth $8,203,608,000 after buying an additional 990,298 shares during the period. Morgan Stanley boosted its stake in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the period. Finally, Capital International Investors lifted its position in Johnson & Johnson by 62.7% in the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after purchasing an additional 10,724,110 shares during the period. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on JNJ. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, February 6th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Finally, Raymond James raised their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $176.14.

View Our Latest Analysis on JNJ

Johnson & Johnson Stock Up 0.2 %

JNJ stock opened at $156.76 on Monday. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The company’s 50 day simple moving average is $158.20 and its 200-day simple moving average is $158.73. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96. The firm has a market capitalization of $377.37 billion, a P/E ratio of 11.35, a P/E/G ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.35 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be paid a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 annualized dividend and a yield of 3.04%. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.